AU2007211846B2 - A method of modulating cellular activity and agents for use therein - Google Patents

A method of modulating cellular activity and agents for use therein Download PDF

Info

Publication number: AU2007211846B2
Authority: AU; Australia
Prior art keywords: tumstatin; tissue; airway; levels; subject
Prior art date: 2006-02-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2007211846A

Other languages

English (en)

Other versions

AU2007211846A1 (en

Inventor

Judith Lee Black

Sarah Boustany

Janette Kay Burgess

Brian Gregory George Oliver

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Sydney

Original Assignee

University of Sydney

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-03

Filing date

2007-02-02

Publication date

2013-05-23

2007-02-02 Application filed by University of Sydney filed Critical University of Sydney

2007-08-09 Publication of AU2007211846A1 publication Critical patent/AU2007211846A1/en

2012-11-29 Assigned to THE UNIVERSITY OF SYDNEY reassignment THE UNIVERSITY OF SYDNEY Request for Assignment Assignors: CRC FOR ASTHMA AND AIRWAYS LTD

2013-05-23 Application granted granted Critical

2013-05-23 Publication of AU2007211846B2 publication Critical patent/AU2007211846B2/en

Status Ceased legal-status Critical Current

2027-02-02 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title claims abstract description 175
230000000694 effects Effects 0.000 title description 26
230000001413 cellular effect Effects 0.000 title description 16
108010012374 type IV collagen alpha3 chain Proteins 0.000 claims abstract description 330
230000014509 gene expression Effects 0.000 claims abstract description 96
239000003795 chemical substances by application Substances 0.000 claims abstract description 74
230000001965 increasing effect Effects 0.000 claims abstract description 38
238000004519 manufacturing process Methods 0.000 claims abstract description 32
108091033319 polynucleotide Proteins 0.000 claims abstract description 20
239000002157 polynucleotide Substances 0.000 claims abstract description 20
102000040430 polynucleotide Human genes 0.000 claims abstract description 20
102100033780 Collagen alpha-3(IV) chain Human genes 0.000 claims abstract 43
208000006673 asthma Diseases 0.000 claims description 166
108010035532 Collagen Proteins 0.000 claims description 80
102000008186 Collagen Human genes 0.000 claims description 80
229920001436 collagen Polymers 0.000 claims description 80
206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims description 73
238000011282 treatment Methods 0.000 claims description 41
210000000621 bronchi Anatomy 0.000 claims description 36
230000003247 decreasing effect Effects 0.000 claims description 28
150000007523 nucleic acids Chemical class 0.000 claims description 28
102000039446 nucleic acids Human genes 0.000 claims description 26
108020004707 nucleic acids Proteins 0.000 claims description 26
108090000765 processed proteins & peptides Proteins 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 23
238000011321 prophylaxis Methods 0.000 claims description 23
239000003814 drug Substances 0.000 claims description 20
201000010099 disease Diseases 0.000 claims description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
230000002829 reductive effect Effects 0.000 claims description 16
238000001514 detection method Methods 0.000 claims description 15
230000001594 aberrant effect Effects 0.000 claims description 12
239000012472 biological sample Substances 0.000 claims description 12
230000001105 regulatory effect Effects 0.000 claims description 12
239000005557 antagonist Substances 0.000 claims description 10
239000003153 chemical reaction reagent Substances 0.000 claims description 10
230000033228 biological regulation Effects 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 9
201000003883 Cystic fibrosis Diseases 0.000 claims description 7
208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 6
230000002222 downregulating effect Effects 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
208000036065 Airway Remodeling Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
230000002441 reversible effect Effects 0.000 claims description 4
238000009007 Diagnostic Kit Methods 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
230000003028 elevating effect Effects 0.000 claims 1
102400000731 Tumstatin Human genes 0.000 description 277
210000001519 tissue Anatomy 0.000 description 259
210000004027 cell Anatomy 0.000 description 72
108090000623 proteins and genes Proteins 0.000 description 51
238000010186 staining Methods 0.000 description 46
210000004072 lung Anatomy 0.000 description 39
241000124008 Mammalia Species 0.000 description 36
238000012216 screening Methods 0.000 description 29
241000699670 Mus sp. Species 0.000 description 28
210000002889 endothelial cell Anatomy 0.000 description 28
150000001875 compounds Chemical class 0.000 description 26
239000000427 antigen Substances 0.000 description 24
108020004999 messenger RNA Proteins 0.000 description 23
108010058846 Ovalbumin Proteins 0.000 description 22
108091007433 antigens Proteins 0.000 description 22
102000036639 antigens Human genes 0.000 description 22
229940092253 ovalbumin Drugs 0.000 description 22
239000000047 product Substances 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 21
235000018102 proteins Nutrition 0.000 description 20
239000000523 sample Substances 0.000 description 19
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
230000033115 angiogenesis Effects 0.000 description 18
238000001574 biopsy Methods 0.000 description 18
230000015572 biosynthetic process Effects 0.000 description 18
239000013598 vector Substances 0.000 description 18
102000004196 processed proteins & peptides Human genes 0.000 description 17
150000001413 amino acids Chemical group 0.000 description 16
210000004204 blood vessel Anatomy 0.000 description 16
-1 ribosomes Proteins 0.000 description 16
229940024606 amino acid Drugs 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 15
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
239000002953 phosphate buffered saline Substances 0.000 description 15
230000002685 pulmonary effect Effects 0.000 description 15
108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
241001465754 Metazoa Species 0.000 description 14
210000005091 airway smooth muscle Anatomy 0.000 description 14
238000003556 assay Methods 0.000 description 14
230000027455 binding Effects 0.000 description 13
108091003079 Bovine Serum Albumin Proteins 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
238000011161 development Methods 0.000 description 12
229940088598 enzyme Drugs 0.000 description 12
239000012091 fetal bovine serum Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
239000012634 fragment Substances 0.000 description 11
229920001184 polypeptide Polymers 0.000 description 11
239000013615 primer Substances 0.000 description 11
206010061218 Inflammation Diseases 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
229940079593 drug Drugs 0.000 description 10
210000002950 fibroblast Anatomy 0.000 description 10
238000003018 immunoassay Methods 0.000 description 10
230000004054 inflammatory process Effects 0.000 description 10
108010047303 von Willebrand Factor Proteins 0.000 description 10
102100036537 von Willebrand factor Human genes 0.000 description 10
229960001134 von willebrand factor Drugs 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
239000004471 Glycine Substances 0.000 description 9
230000002055 immunohistochemical effect Effects 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 8
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 8
239000000556 agonist Substances 0.000 description 8
230000010085 airway hyperresponsiveness Effects 0.000 description 8
229960002329 methacholine Drugs 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
239000012188 paraffin wax Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
230000009467 reduction Effects 0.000 description 8
238000006722 reduction reaction Methods 0.000 description 8
230000004044 response Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
230000001684 chronic effect Effects 0.000 description 7
230000007423 decrease Effects 0.000 description 7
230000000670 limiting effect Effects 0.000 description 7
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 7
208000023504 respiratory system disease Diseases 0.000 description 7
239000000758 substrate Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
230000014616 translation Effects 0.000 description 7
238000007492 two-way ANOVA Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
108010001336 Horseradish Peroxidase Proteins 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
238000007792 addition Methods 0.000 description 6
230000037396 body weight Effects 0.000 description 6
229910002091 carbon monoxide Inorganic materials 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
210000002460 smooth muscle Anatomy 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
108091026890 Coding region Proteins 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
208000037883 airway inflammation Diseases 0.000 description 5
230000008827 biological function Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000003828 downregulation Effects 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000005714 functional activity Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000001543 one-way ANOVA Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
230000000241 respiratory effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
241000894007 species Species 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
230000003827 upregulation Effects 0.000 description 5
108020004463 18S ribosomal RNA Proteins 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
239000013566 allergen Substances 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
230000008021 deposition Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
230000002427 irreversible effect Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000463 material Substances 0.000 description 4
229930014626 natural product Natural products 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000002245 particle Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
229920001296 polysiloxane Polymers 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000013589 supplement Substances 0.000 description 4
238000013519 translation Methods 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
239000004971 Cross linker Substances 0.000 description 3
206010013975 Dyspnoeas Diseases 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
229910052693 Europium Inorganic materials 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
102000003992 Peroxidases Human genes 0.000 description 3
238000011529 RT qPCR Methods 0.000 description 3
208000037656 Respiratory Sounds Diseases 0.000 description 3
102000004338 Transferrin Human genes 0.000 description 3
108090000901 Transferrin Proteins 0.000 description 3
208000026911 Tuberous sclerosis complex Diseases 0.000 description 3
206010047924 Wheezing Diseases 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
239000012122 aqueous mounting media Substances 0.000 description 3
239000003124 biologic agent Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
208000023819 chronic asthma Diseases 0.000 description 3
238000002591 computed tomography Methods 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
239000000284 extract Substances 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000002085 irritant Substances 0.000 description 3
231100000021 irritant Toxicity 0.000 description 3
239000003446 ligand Substances 0.000 description 3
238000002483 medication Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
239000012581 transferrin Substances 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
208000009999 tuberous sclerosis Diseases 0.000 description 3
108010072106 tumstatin (74-98) Proteins 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 2
OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
GAUBNQMYYJLWNF-UHFFFAOYSA-N 3-(Carboxymethylamino)propanoic acid Chemical compound OC(=O)CCNCC(O)=O GAUBNQMYYJLWNF-UHFFFAOYSA-N 0.000 description 2
DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000167854 Bourreria succulenta Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
208000000059 Dyspnea Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010038997 Retroviral infections Diseases 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
235000019485 Safflower oil Nutrition 0.000 description 2
108010077895 Sarcosine Proteins 0.000 description 2
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
210000005058 airway cell Anatomy 0.000 description 2
210000005057 airway smooth muscle cell Anatomy 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
229940067621 aminobutyrate Drugs 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000000074 antisense oligonucleotide Substances 0.000 description 2
238000012230 antisense oligonucleotides Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000003123 bronchiole Anatomy 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000021235 carbamoylation Effects 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
108091092328 cellular RNA Proteins 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000004737 colorimetric analysis Methods 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
239000002385 cottonseed oil Substances 0.000 description 2
XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
239000003344 environmental pollutant Substances 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000003352 fibrogenic effect Effects 0.000 description 2
238000002509 fluorescent in situ hybridization Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000008098 formaldehyde solution Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
238000013537 high throughput screening Methods 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
238000009533 lab test Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
238000001638 lipofection Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229960001913 mecysteine Drugs 0.000 description 2
229910052751 metal Chemical class 0.000 description 2
239000002184 metal Chemical class 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000002688 persistence Effects 0.000 description 2
OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
231100000719 pollutant Toxicity 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
235000005713 safflower oil Nutrition 0.000 description 2
239000003813 safflower oil Substances 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
230000037390 scarring Effects 0.000 description 2
229910052711 selenium Inorganic materials 0.000 description 2
239000011669 selenium Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000008685 targeting Effects 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000008719 thickening Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
CWLQUGTUXBXTLF-RXMQYKEDSA-N (2r)-1-methylpyrrolidine-2-carboxylic acid Chemical compound CN1CCC[C@@H]1C(O)=O CWLQUGTUXBXTLF-RXMQYKEDSA-N 0.000 description 1
SCIFESDRCALIIM-SECBINFHSA-N (2r)-2-(methylazaniumyl)-3-phenylpropanoate Chemical compound CN[C@@H](C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-SECBINFHSA-N 0.000 description 1
CZCIKBSVHDNIDH-LLVKDONJSA-N (2r)-3-(1h-indol-3-yl)-2-(methylamino)propanoic acid Chemical compound C1=CC=C2C(C[C@@H](NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-LLVKDONJSA-N 0.000 description 1
LNSMPSPTFDIWRQ-GSVOUGTGSA-N (2r)-4-amino-2-(methylamino)-4-oxobutanoic acid Chemical compound CN[C@@H](C(O)=O)CC(N)=O LNSMPSPTFDIWRQ-GSVOUGTGSA-N 0.000 description 1
NTWVQPHTOUKMDI-RXMQYKEDSA-N (2r)-5-(diaminomethylideneamino)-2-(methylamino)pentanoic acid Chemical compound CN[C@@H](C(O)=O)CCCNC(N)=N NTWVQPHTOUKMDI-RXMQYKEDSA-N 0.000 description 1
KSPIYJQBLVDRRI-NTSWFWBYSA-N (2r,3s)-3-methyl-2-(methylazaniumyl)pentanoate Chemical compound CC[C@H](C)[C@@H](NC)C(O)=O KSPIYJQBLVDRRI-NTSWFWBYSA-N 0.000 description 1
BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
LDUWTIUXPVCEQF-LURJTMIESA-N (2s)-2-(cyclopentylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1CCCC1 LDUWTIUXPVCEQF-LURJTMIESA-N 0.000 description 1
HOKKHZGPKSLGJE-VKHMYHEASA-N (2s)-2-(methylamino)butanedioic acid Chemical compound CN[C@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-VKHMYHEASA-N 0.000 description 1
FPDYKABXINADKS-LURJTMIESA-N (2s)-2-(methylazaniumyl)hexanoate Chemical compound CCCC[C@H](NC)C(O)=O FPDYKABXINADKS-LURJTMIESA-N 0.000 description 1
HCPKYUNZBPVCHC-YFKPBYRVSA-N (2s)-2-(methylazaniumyl)pentanoate Chemical compound CCC[C@H](NC)C(O)=O HCPKYUNZBPVCHC-YFKPBYRVSA-N 0.000 description 1
IUYZJPXOXGRNNE-ZETCQYMHSA-N (2s)-2-[cyclopentyl(methyl)amino]propanoic acid Chemical compound OC(=O)[C@H](C)N(C)C1CCCC1 IUYZJPXOXGRNNE-ZETCQYMHSA-N 0.000 description 1
KWWFNGCKGYUCLC-RXMQYKEDSA-N (2s)-3,3-dimethyl-2-(methylamino)butanoic acid Chemical compound CN[C@H](C(O)=O)C(C)(C)C KWWFNGCKGYUCLC-RXMQYKEDSA-N 0.000 description 1
AXDLCFOOGCNDST-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-N 0.000 description 1
XKZCXMNMUMGDJG-AWEZNQCLSA-N (2s)-3-[(6-acetylnaphthalen-2-yl)amino]-2-aminopropanoic acid Chemical compound C1=C(NC[C@H](N)C(O)=O)C=CC2=CC(C(=O)C)=CC=C21 XKZCXMNMUMGDJG-AWEZNQCLSA-N 0.000 description 1
LNSMPSPTFDIWRQ-VKHMYHEASA-N (2s)-4-amino-2-(methylamino)-4-oxobutanoic acid Chemical compound CN[C@H](C(O)=O)CC(N)=O LNSMPSPTFDIWRQ-VKHMYHEASA-N 0.000 description 1
XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 1
KSZFSNZOGAXEGH-BYPYZUCNSA-N (2s)-5-amino-2-(methylamino)-5-oxopentanoic acid Chemical compound CN[C@H](C(O)=O)CCC(N)=O KSZFSNZOGAXEGH-BYPYZUCNSA-N 0.000 description 1
OZRWQPFBXDVLAH-YFKPBYRVSA-N (2s)-5-amino-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CCCN OZRWQPFBXDVLAH-YFKPBYRVSA-N 0.000 description 1
RHMALYOXPBRJBG-WXHCCQJTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s,3r)-2-[[(2s)-2-[[2-[[2-[[(2r)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]- Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RHMALYOXPBRJBG-WXHCCQJTSA-N 0.000 description 1
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
WAAJQPAIOASFSC-UHFFFAOYSA-N 2-(1-hydroxyethylamino)acetic acid Chemical compound CC(O)NCC(O)=O WAAJQPAIOASFSC-UHFFFAOYSA-N 0.000 description 1
UEQSFWNXRZJTKB-UHFFFAOYSA-N 2-(2,2-diphenylethylamino)acetic acid Chemical compound C=1C=CC=CC=1C(CNCC(=O)O)C1=CC=CC=C1 UEQSFWNXRZJTKB-UHFFFAOYSA-N 0.000 description 1
PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
XCDGCRLSSSSBIA-UHFFFAOYSA-N 2-(2-methylsulfanylethylamino)acetic acid Chemical compound CSCCNCC(O)=O XCDGCRLSSSSBIA-UHFFFAOYSA-N 0.000 description 1
STMXJQHRRCPJCJ-UHFFFAOYSA-N 2-(3,3-diphenylpropylamino)acetic acid Chemical compound C=1C=CC=CC=1C(CCNCC(=O)O)C1=CC=CC=C1 STMXJQHRRCPJCJ-UHFFFAOYSA-N 0.000 description 1
OGAULEBSQQMUKP-UHFFFAOYSA-N 2-(4-aminobutylamino)acetic acid Chemical compound NCCCCNCC(O)=O OGAULEBSQQMUKP-UHFFFAOYSA-N 0.000 description 1
KGSVNOLLROCJQM-UHFFFAOYSA-N 2-(benzylamino)acetic acid Chemical compound OC(=O)CNCC1=CC=CC=C1 KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 1
KFDPCYZHENQOBV-UHFFFAOYSA-N 2-(bromomethyl)-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1CBr KFDPCYZHENQOBV-UHFFFAOYSA-N 0.000 description 1
IVCQRTJVLJXKKJ-UHFFFAOYSA-N 2-(butan-2-ylazaniumyl)acetate Chemical compound CCC(C)NCC(O)=O IVCQRTJVLJXKKJ-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
KQLGGQARRCMYGD-UHFFFAOYSA-N 2-(cyclobutylamino)acetic acid Chemical compound OC(=O)CNC1CCC1 KQLGGQARRCMYGD-UHFFFAOYSA-N 0.000 description 1
DICMQVOBSKLBBN-UHFFFAOYSA-N 2-(cyclodecylamino)acetic acid Chemical compound OC(=O)CNC1CCCCCCCCC1 DICMQVOBSKLBBN-UHFFFAOYSA-N 0.000 description 1
NPLBBQAAYSJEMO-UHFFFAOYSA-N 2-(cycloheptylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCCCC1 NPLBBQAAYSJEMO-UHFFFAOYSA-N 0.000 description 1
OQMYZVWIXPPDDE-UHFFFAOYSA-N 2-(cyclohexylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCCC1 OQMYZVWIXPPDDE-UHFFFAOYSA-N 0.000 description 1
PNKNDNFLQNMQJL-UHFFFAOYSA-N 2-(cyclooctylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCCCCC1 PNKNDNFLQNMQJL-UHFFFAOYSA-N 0.000 description 1
DXQCCQKRNWMECV-UHFFFAOYSA-N 2-(cyclopropylazaniumyl)acetate Chemical compound OC(=O)CNC1CC1 DXQCCQKRNWMECV-UHFFFAOYSA-N 0.000 description 1
PRVOMNLNSHAUEI-UHFFFAOYSA-N 2-(cycloundecylamino)acetic acid Chemical compound OC(=O)CNC1CCCCCCCCCC1 PRVOMNLNSHAUEI-UHFFFAOYSA-N 0.000 description 1
HEPOIJKOXBKKNJ-UHFFFAOYSA-N 2-(propan-2-ylazaniumyl)acetate Chemical compound CC(C)NCC(O)=O HEPOIJKOXBKKNJ-UHFFFAOYSA-N 0.000 description 1
AWEZYTUWDZADKR-UHFFFAOYSA-N 2-[(2-amino-2-oxoethyl)azaniumyl]acetate Chemical compound NC(=O)CNCC(O)=O AWEZYTUWDZADKR-UHFFFAOYSA-N 0.000 description 1
MNDBDVPDSHGIHR-UHFFFAOYSA-N 2-[(3-amino-3-oxopropyl)amino]acetic acid Chemical compound NC(=O)CCNCC(O)=O MNDBDVPDSHGIHR-UHFFFAOYSA-N 0.000 description 1
YDBPFLZECVWPSH-UHFFFAOYSA-N 2-[3-(diaminomethylideneamino)propylamino]acetic acid Chemical compound NC(=N)NCCCNCC(O)=O YDBPFLZECVWPSH-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
101800000535 3C-like proteinase Proteins 0.000 description 1
101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
241000238876 Acari Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
239000004429 Calibre Substances 0.000 description 1
241000282421 Canidae Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 1
AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 1
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
229930195711 D-Serine Natural products 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
229930028154 D-arginine Natural products 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
229930182847 D-glutamic acid Natural products 0.000 description 1
ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
229930195715 D-glutamine Natural products 0.000 description 1
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
229930195721 D-histidine Natural products 0.000 description 1
229930182845 D-isoleucine Natural products 0.000 description 1
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
229930182819 D-leucine Natural products 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
229930182818 D-methionine Natural products 0.000 description 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
229930182832 D-phenylalanine Natural products 0.000 description 1
229930182820 D-proline Natural products 0.000 description 1
AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
229930182822 D-threonine Natural products 0.000 description 1
229930182827 D-tryptophan Natural products 0.000 description 1
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
229930195709 D-tyrosine Natural products 0.000 description 1
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
229930182831 D-valine Natural products 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
108091027757 Deoxyribozyme Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010013700 Drug hypersensitivity Diseases 0.000 description 1
229930195710 D‐cysteine Natural products 0.000 description 1
UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000016970 Follistatin Human genes 0.000 description 1
108010014612 Follistatin Proteins 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
240000001238 Gaultheria procumbens Species 0.000 description 1
235000007297 Gaultheria procumbens Nutrition 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000946053 Homo sapiens Lysosomal-associated transmembrane protein 4A Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
GDFAOVXKHJXLEI-UHFFFAOYSA-N L-N-Boc-N-methylalanine Natural products CNC(C)C(O)=O GDFAOVXKHJXLEI-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
102100034728 Lysosomal-associated transmembrane protein 4A Human genes 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
241000289619 Macropodidae Species 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
102000016349 Myosin Light Chains Human genes 0.000 description 1
108010067385 Myosin Light Chains Proteins 0.000 description 1
CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 1
CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 1
GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
XLBVNMSMFQMKEY-BYPYZUCNSA-N N-methyl-L-glutamic acid Chemical compound CN[C@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-BYPYZUCNSA-N 0.000 description 1
YAXAFCHJCYILRU-YFKPBYRVSA-N N-methyl-L-methionine Chemical compound C[NH2+][C@H](C([O-])=O)CCSC YAXAFCHJCYILRU-YFKPBYRVSA-N 0.000 description 1
SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 description 1
101150054880 NASP gene Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
150000007930 O-acyl isoureas Chemical class 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000233805 Phoenix Species 0.000 description 1
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
208000005279 Status Asthmaticus Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
102000005421 acetyltransferase Human genes 0.000 description 1
108020002494 acetyltransferase Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
210000001552 airway epithelial cell Anatomy 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000008848 allosteric regulation Effects 0.000 description 1
UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940093740 amino acid and derivative Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
208000009887 angiolipoma Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
238000003491 array Methods 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
238000013276 bronchoscopy Methods 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
229940080593 budesonide / formoterol Drugs 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000007958 cherry flavor Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
AWGTVRDHKJQFAX-UHFFFAOYSA-M chloro(phenyl)mercury Chemical compound Cl[Hg]C1=CC=CC=C1 AWGTVRDHKJQFAX-UHFFFAOYSA-M 0.000 description 1
VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
108010007093 dispase Proteins 0.000 description 1
238000009510 drug design Methods 0.000 description 1
SQNZJJAZBFDUTD-UHFFFAOYSA-N durene Chemical compound CC1=CC(C)=C(C)C=C1C SQNZJJAZBFDUTD-UHFFFAOYSA-N 0.000 description 1
239000000428 dust Substances 0.000 description 1
UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
238000001839 endoscopy Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
230000008472 epithelial growth Effects 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
229960001022 fenoterol Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229940114006 fluticasone / salmeterol Drugs 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
229940015043 glyoxal Drugs 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
210000005120 human airway smooth muscle cell Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000004047 hyperresponsiveness Effects 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
230000003434 inspiratory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229940124625 intravenous corticosteroids Drugs 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910021644 lanthanide ion Inorganic materials 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000004807 localization Effects 0.000 description 1
229940125386 long-acting bronchodilator Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
230000004199 lung function Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000013528 metallic particle Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229940078547 methylserine Drugs 0.000 description 1
238000001531 micro-dissection Methods 0.000 description 1
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
229960003248 mifepristone Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
229960001951 montelukast sodium Drugs 0.000 description 1
LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
230000003843 mucus production Effects 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
229960002259 nedocromil sodium Drugs 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
229960000470 omalizumab Drugs 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
229940124624 oral corticosteroid Drugs 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
230000032361 posttranscriptional gene silencing Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
229960001327 pyridoxal phosphate Drugs 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
238000012797 qualification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
238000012764 semi-quantitative analysis Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940125387 short-acting bronchodilator Drugs 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000000779 smoke Substances 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
229960002117 triamcinolone acetonide Drugs 0.000 description 1
229940035722 triiodothyronine Drugs 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
239000008096 xylene Substances 0.000 description 1
229960004764 zafirlukast Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2007211846A 2006-02-03 2007-02-02 A method of modulating cellular activity and agents for use therein Ceased AU2007211846B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US76483306P	2006-02-03	2006-02-03
US60/764,833		2006-02-03
PCT/AU2007/000106 WO2007087689A1 (fr)	2006-02-03	2007-02-02	Procede de modulation de l'activite cellulaire et agents a utiliser dans le cadre de celui-ci

Publications (2)

Publication Number	Publication Date
AU2007211846A1 AU2007211846A1 (en)	2007-08-09
AU2007211846B2 true AU2007211846B2 (en)	2013-05-23

Family

ID=38327093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2007211846A Ceased AU2007211846B2 (en)	2006-02-03	2007-02-02	A method of modulating cellular activity and agents for use therein

Country Status (5)

Country	Link
US (2)	US8227419B2 (fr)
EP (2)	EP2468294A1 (fr)
AT (1)	ATE551067T1 (fr)
AU (1)	AU2007211846B2 (fr)
WO (1)	WO2007087689A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2012529438A (ja) *	2009-06-09	2012-11-22	シーアールシーフォーアズマアンドエアウェイズリミテッド	治療方法
MX2013009647A (es) *	2011-02-21	2014-02-03	Fibrostatin S L	Metodos para tratar y diagnosticar enfermedades.
EP2744831B1 (fr)	2011-08-17	2017-12-06	The Regents of the University of Colorado, A Body Corporate	Protéine de fusion à base de transferrine et de tumstatine et procédés de production et d'utilisation associés
JP6789961B2 (ja) *	2015-03-06	2020-11-25	ジョージア・ステイト・ユニヴァーシティ・リサーチ・ファウンデイション，インコーポレイテッド	インテグリン標的タンパク質およびその使用方法
GB201721387D0 (en) *	2017-12-20	2018-01-31	Nordic Bioscience As	Tumstatin assay

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005103281A2 (fr) *	2004-04-26	2005-11-03	Children's Medical Center Corporation	Biomarqueurs de plaquettes utilises dans le diagnostic de maladies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4019653A (en)	1975-08-22	1977-04-26	Graco Inc.	Automatic proportioning paint spray system
US4016043A (en)	1975-09-04	1977-04-05	Akzona Incorporated	Enzymatic immunological method for the determination of antigens and antibodies
US4843000A (en)	1979-12-26	1989-06-27	Syntex (U.S.A.) Inc.	Simultaneous calibration heterogeneous immunoassay
US4849338A (en)	1982-07-16	1989-07-18	Syntex (U.S.A.) Inc.	Simultaneous calibration heterogeneous immunoassay
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
US4424279A (en)	1982-08-12	1984-01-03	Quidel	Rapid plunger immunoassay method and apparatus
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5453517A (en)	1992-02-25	1995-09-26	Molecular Probes, Inc.	Reactive derivatives of bapta used to make ion-selective chelators
US5405975A (en)	1993-03-29	1995-04-11	Molecular Probes, Inc.	Fluorescent ion-selective diaryldiaza crown ether conjugates
US5723218A (en)	1990-04-16	1998-03-03	Molecular Probes, Inc.	Dipyrrometheneboron difluoride labeled flourescent microparticles
US5274113A (en)	1991-11-01	1993-12-28	Molecular Probes, Inc.	Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5326692B1 (en)	1992-05-13	1996-04-30	Molecular Probes Inc	Fluorescent microparticles with controllable enhanced stokes shift
US5433896A (en)	1994-05-20	1995-07-18	Molecular Probes, Inc.	Dibenzopyrrometheneboron difluoride dyes
US5459276A (en)	1994-05-20	1995-10-17	Molecular Probes, Inc.	Benzazolylcoumarin-based ion indicators for heavy metals
US5648270A (en)	1995-02-06	1997-07-15	Molecular Probes, Inc.	Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5227487A (en)	1990-04-16	1993-07-13	Molecular Probes, Inc.	Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
DK0604552T3 (da)	1991-09-18	1997-08-04	Affymax Tech Nv	Fremgangsmåde til syntese af forskellige samlinger af oligomerer
US5763263A (en)	1995-11-27	1998-06-09	Dehlinger; Peter J.	Method and apparatus for producing position addressable combinatorial libraries
US5753187A (en)	1996-06-14	1998-05-19	Stovall Life Science, Inc.	Combinatorial chemistry cassette
US7387779B2 (en)	1998-06-17	2008-06-17	Beth Israel Deaconess Medical Center	Anti-angiogenic proteins and fragments and methods of use thereof
WO2000059532A1 (fr)	1999-04-01	2000-10-12	Biostratum, Inc.	Utilisation de domaine de collagene de type iv permettant d'inhiber l'angiogenese et la croissance tumorale
EP1337633A2 (fr) *	2000-01-07	2003-08-27	Beth Israel Deaconess Medical Center	Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
WO2006044614A2 (fr) *	2004-10-14	2006-04-27	Sopherion Therapeutics, Inc.	Peptides anti-angiogeniques et procedes d'utilisation de ceux-ci
WO2006128027A1 (fr)	2005-05-26	2006-11-30	Peptx, Inc.	Peptides recombinants fonctionnellement actifs, methodes de fabrication et interactions avec d'autres peptides
US20100144641A1 (en) *	2005-09-12	2010-06-10	Popel Aleksander S	Compositions Having Antiangiogenic Activity and Uses Thereof

2007
- 2007-02-02 WO PCT/AU2007/000106 patent/WO2007087689A1/fr not_active Ceased
- 2007-02-02 EP EP12151311A patent/EP2468294A1/fr not_active Withdrawn
- 2007-02-02 US US12/278,266 patent/US8227419B2/en not_active Expired - Fee Related
- 2007-02-02 AU AU2007211846A patent/AU2007211846B2/en not_active Ceased
- 2007-02-02 EP EP07710533A patent/EP1988915B1/fr not_active Not-in-force
- 2007-02-02 AT AT07710533T patent/ATE551067T1/de active
2012
- 2012-07-12 US US13/547,944 patent/US20120283192A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005103281A2 (fr) *	2004-04-26	2005-11-03	Children's Medical Center Corporation	Biomarqueurs de plaquettes utilises dans le diagnostic de maladies

Also Published As

Publication number	Publication date
EP1988915A4 (fr)	2009-11-11
WO2007087689A1 (fr)	2007-08-09
US20090221494A1 (en)	2009-09-03
US8227419B2 (en)	2012-07-24
EP1988915B1 (fr)	2012-03-28
ATE551067T1 (de)	2012-04-15
EP2468294A1 (fr)	2012-06-27
AU2007211846A1 (en)	2007-08-09
EP1988915A1 (fr)	2008-11-12
US20120283192A1 (en)	2012-11-08

Publication	Publication Date	Title
Kim et al.	2002	PTEN and TNF-α regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-κB–dependent pathway
US20060172347A1 (en)	2006-08-03	Method of diagnosis, treatment and useful agents for conditions characterised by modulation in the level of activin ssc
Chen et al.	2021	Knockdown of circROBO2 attenuates acute myocardial infarction through regulating the miR-1184/TRADD axis
CA2541237C (fr)	2015-12-01	Modulation de l'activine pour modifier les reactions inflammatoires
WO2003080640A1 (fr)	2003-10-02	Genes de cellules endotheliales sanguines et lymphatiques
AU2007211846B2 (en)	2013-05-23	A method of modulating cellular activity and agents for use therein
US20170016004A1 (en)	2017-01-19	DDX5 AND ASSOCIATED NON-CODING RNAs AND MODULATION OF TH17 EFFECTOR FUNCTION
AU2009212828A1 (en)	2009-09-17	Therapeutic, Prophylactic and Diagnostic Agents
AU2004224825A1 (en)	2004-10-07	Therapeutic and prophylactic compositions and uses therefor
US8697050B2 (en)	2014-04-15	Methods of treatment using a vector encoding p21/Cip1
CN111979328B (zh)	2022-10-14	一种预测肝癌肺转移的生物标志物及其应用
CA2520711A1 (fr)	2004-10-07	Procede et agents diagnostiques et therapeutiques
EP4454663A1 (fr)	2024-10-30	Agent thérapeutique ou prophylactique pour la crise cardiaque, la fibrose cardiaque ou l'insuffisance cardiaque, dans lequel htra3 est la cible thérapeutique
Zhong et al.	2025	Cardiomyocyte‐Enriched USP20 Ameliorates Pathological Cardiac Hypertrophy by Targeting STAT3 Deubiquitination
JPWO2001021793A1 (ja)	2003-04-08	ｐ２１Ｃｉｐ１リウマチ治療剤
Jiang et al.	2025	A novel feedback loop: CELF1/circ-CELF1/BRPF3/KAT7 in cardiac fibrosis
Yang et al.	2025	Cardiac fibroblasts-specific USP7 drives post-infarction cardiac fibrosis by deubiquitinating Krüppel-like factor 7 to promote myofibroblast activation
JP2006518998A (ja)	2006-08-24	Ｐａｃ−１（ｄｕｓｐ２）を使用する炎症性疾患の診断方法及び治療方法
WO2011153590A1 (fr)	2011-12-15	Utilisation de l'interferon epsilon dans des procédés de diagnostic et de traitement
CN119367539A (zh)	2025-01-28	Sirt2蛋白在通过stat3-cdkn2b信号通路延缓机体心脏衰老中的应用
AU2003287765A1 (en)	2004-06-30	Method of diagnosis,treatment and useful agents for conditions characterised by modulation in the level of activin betac.
MXPA06010108A (es)	2008-10-10	Protocolos de diagnostico.
AU2004277281A1 (en)	2005-04-14	Therapeutic method

Legal Events

Date	Code	Title	Description
2012-11-29	PC1	Assignment before grant (sect. 113)	Owner name: THE UNIVERSITY OF SYDNEY Free format text: FORMER APPLICANT(S): CRC FOR ASTHMA AND AIRWAYS LTD
2013-09-19	FGA	Letters patent sealed or granted (standard patent)
2014-08-28	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Date

Code

Title

Description

2012-11-29

PC1

Assignment before grant (sect. 113)

Owner name: THE UNIVERSITY OF SYDNEY

Free format text: FORMER APPLICANT(S): CRC FOR ASTHMA AND AIRWAYS LTD

2013-09-19

FGA

Letters patent sealed or granted (standard patent)

2014-08-28

MK14

Patent ceased section 143(a) (annual fees not paid) or expired